Pancreatic Cancer Detection Consortium (PCDC)

A 3-dimensional image of a human torso highlighting the pancreas.The Pancreatic Cancer Detection Consortium (PCDC) develops and tests new molecular and imaging biomarkers to detect early stage pancreatic ductal adenocarcinoma (PDAC) and its precursor lesions.  These biomarkers would be used to identify individuals who are at high risk of developing PDAC and are candidates for early intervention.

Read more About PCDC

Teams

  • Beckman Research Institute, City of Hope Comprehensive Cancer Center/Translational Genomics Research Institute
  • Dana Farber Cancer Institute/Harvard Medical School
  • Johns Hopkins University
  • Mayo Clinic/University of Pennsylvania
  • Stanford University
  • The University of Texas MD Anderson Cancer Center
  • University of California, Davis
  • University of Nebraska Medical Center

More about the Teams

PCDC Resources and Collaborative Opportunities

  • Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC)
     
  • Alliance of Pancreatic Cancer Consortia for Biomarkers for Early Detection

Read more about PCDC Resources and Collaborative Opportunities

Administration

  • Structure
  • Steering Committee
  • Consortium Coordinator
  • NCI Program Staff

Learn about Administration

News and Events

This page is under construction.

See all News and Events

New Onset Diabetes Cohort Sought to Unravel Complexities of Pancreatic Cancer Development

The National Cancer Institute is leading a project to create a cohort of people who are newly diagnosed with diabetes in the hopes that this group, who are at increased risk of developing pancreatic cancer, provide the clues in their blood and tissues to unravel some of the unknowns about this highly fatal cancer. The New Onset Diabetes Study (NOD) will include 10,000 people ages 50 to 85...